after joining the study you sign a consent form that explains the purpose of the follow‑up and the information that will be collected.

your personal and medical information is entered into the study record and a schedule of future visits is created.

a baseline visit is performed to record your current health status, including a physical examination and a review of your medical history.

blood samples are taken to measure the level of the ucart19 transgene and to check routine laboratory values.

if a bone‑marrow sample is part of your routine care, it may be collected at this time for optional analysis.

for paediatric participants a growth assessment is done to establish a reference for future comparison.

the study follows patients who have already received a single intravenous infusion of the cell product s68587.

the product is supplied as a suspension for infusion with concentrations such as 20 megacells per milliliter, 15 megacells per milliliter, 6 megacells per milliliter, or 0.6 megacells per milliliter.

the dose is expressed in the number of cells rather than milligrams, and the infusion is given only once.

you attend scheduled clinic visits, typically every month, for the first year after the last ucart19 infusion.

at each visit you report any side effects, which are called adverse events, and the study team records their duration and outcome.

blood tests are repeated to monitor the level of the transgene and other safety laboratory values.

paediatric participants receive growth monitoring at each visit to assess any impact on height and puberty.

any serious side effect that could lead to death is documented and followed closely.

after the first year, visits continue at longer intervals, such as every six months, until the planned study end date in 2035.

the same assessments are performed: reporting of adverse events, blood sampling for transgene levels, and optional bone‑marrow sampling if it is part of routine care.

additional evaluations include checking for disease relapse or progression, and recording overall survival information.

paediatric growth assessments continue as needed.

at the final visit the study team collects the last set of safety and laboratory data.

all information collected during the study is reviewed and entered into the study database for final analysis.